William (“Bill”) J. Gedale serves as the Company’s Executive Chairman. Bill is an experienced investor, financial professional and biotech founder. He has been in the investment business since 1965. He is a co-founder and Chairman of Promosome, and Chairman of PIN Pharma. Previously, Mr. Gedale co-founded NGN Capital, a trans-Atlantic life-sciences venture fund, founded Mount Everest Advisors, and served as an investment advisor to individuals and as a full-time consultant to Warburg-Pincus Capital Management, the world's largest venture capital firm. Before founding Mount Everest Advisors he was a Managing Director at John W. Bristol & Co. and President & Chief Executive Officer of General American Investors. Mr. Gedale has been a director of Board of KIKA Medical Inc. (acquired by Merge Healthcare), BioArray Solutions (acquired by Immucor), Unilab (acquired by Kelso), Allied Clinical Labs (acquired by Labcorp), Bioreliance (acquired by Sigma-Aldrich), U.S. Home Health Care, GAMCO and General American Investors. William Gedale holds an M.B.A. from New York University, a J.D. from Fordham Law School, and an A.B. from Syracuse University.

Dr. Bernard M. Peperstraete is CEO and co-founder of Acuamark Diagnostics, Inc. Bernard is a medical entrepreneur, and has been involved in operating in, founding and investing in life science businesses for over 20 years; Prior to Acuamark, Bernard ran ACT Biotech, a cancer pharmaceutical company (acquired by Eddingpharm). Earlier, Bernard was involved in healthcare venture capital for nearly a decade, most recently as a Partner at NGN Capital. Bernard ed on the boards of Exosome Diagnostics (acquired by Bio-Techne), ACT Biotech and Potentia Pharma (aka APLS:NASDAQ), and was closely involved with a number of transactions, e.g. Santhera (SANN:SIX) and Artisan Pharma (acquired by AKP). Before completing his MBA at Harvard, Bernard worked on emerging market opportunities at Novartis in Basel, was a Deputy Director at the Tan Tock Seng Hospital in Singapore (during the SARS crisis) and successfully co-founded and ran a contract research business, also in Singapore. In 1999, after serving as a physician, Dr. Peperstraete managed the HIV business unit at Bristol Myers & Squibb, Singapore. MD, Katholieke Universiteit Leuven, Belgium; DTMIH, Institute of Tropical Medicine, BelgiumMBA, Harvard Business School.

Greg has spent the last decades working full time with early stage companies as a super angel, board member, lead investor, and advisor. Greg is a partner in Saunders Murdock Associates, a super angel partnership that invests in early stage technology and life science companies. In this role, Greg is actively involved in many portfolio companies where he works with CEO’s on strategy, fundraising and communications. Saunders Murdock Associates LLC has made multiple investments, building a portfolio of approximately 25 early stage companies sourced from Boston, MA and Louisville, KY. The focus of this portfolio is life science and technology companies.

Managing Director at Argent Ventures LLC; Board Director of Coferon Inc.; Board of Directors of the Fund for Public Health of New York, a Public-Private Partnership; Experienced biotech investor, financial professional and real-estate investor.

Early in his career, Dr. Vuletic was a cancer researcher at Children’s Hospital Boston and Harvard Medical School. After receiving an MBA from Harvard, he was a member of the Roche Pharma Biomarker strategy team, worked at Booz Allen Hamilton and was a hedge fund investor. Dr. Vuletic served on the Board at a mid-size pharmaceutical company in the emerging markets which was successfully sold to a multinational Pharma company. He is a board-certified physician and active biotech investor.